title: Enhanced low-density lipoprotein cholesterol reduction and cost-effectiveness by low-dose colestipol plus lovastatin combination therapy.
abstract: A total of 96 patients with moderate elevations of low-density lipoprotein (LDL) cholesterol were randomly assigned to 4 different double-blind treatment regimens: placebo; colestipol 5 g and lovastatin 20 mg/day (C5 + L20); colestipol 10 g and lovastatin 20 mg/day (C10 + L20); and lovastatin 40 mg/day (L40). During 12 weeks of therapy, C10 + L20 achieved the greatest reduction in total cholesterol (-32%) and LDL cholesterol (-48%) levels from baseline. This combination also exhibited significantly greater reductions in LDL cholesterol levels than the C5 + L20 and L40 groups (p < 0.01). The differences in total and LDL cholesterol reduction between the C5 + L20 and L40 groups were not significant. Similar changes and differences between treatments were seen in apolipoprotein B levels. Whereas mean total apolipoprotein A-I levels increased with all treatments (p < 0.05), lipoprotein particles A-I were significantly increased in the C10 + L20 group (p < 0.01) only. Results demonstrate that the combination of low-dose lovastatin (20 mg/day) with low-dose colestipol (5 or 10 g/day) produces LDL cholesterol reductions equal to or greater than higher doses of lovastatin (40 mg/day). In addition, low-dose combinations are > 25% more cost-effective than high-dose monotherapy.
authors: Department of Preventive Medicine, University of Iowa College of Medicine, Iowa City.
authors: H G
authors: HG
authors: Schrott
authors: E A
authors: EA
authors: Stein
authors: C A
authors: CA
authors: Dujovne
authors: M H
authors: MH
authors: Davidson
authors: G B
authors: GB
authors: Goris
authors: T H
authors: TH
authors: Oliphant
authors: J C
authors: JC
authors: Phillips
authors: G G
authors: GG
authors: Shawaryn
mesh_terms: D001053:Apolipoproteins / Q000097:blood; D008078:Cholesterol, LDL / Q000097:blood*; D003084:Colestipol / Q000008:administration & dosage / Q000627:therapeutic use*; D003362:Cost-Benefit Analysis; D004311:Double-Blind Method; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D006937:Hypercholesterolemia / Q000097:blood* / Q000188:drug therapy* / Q000191:economics; D008055:Lipids / Q000097:blood; D008074:Lipoproteins / Q000097:blood; D008148:Lovastatin / Q000008:administration & dosage / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged
chemical_list: D001053:Apolipoproteins; D008078:Cholesterol, LDL; D008055:Lipids; D008074:Lipoproteins; D008148:Lovastatin; D003084:Colestipol